Core Viewpoint - Bionano Genomics, Inc. has announced a public offering of 5,000,000 shares of common stock and associated Series E and Series F warrants, aiming to raise approximately $10 million before expenses, with potential additional proceeds of about $20 million if the warrants are fully exercised [1][3]. Group 1: Offering Details - The public offering price is set at $2.00 per share, with Series E warrants expiring in five years and Series F warrants expiring in eighteen months [1]. - The offering is expected to close on or about September 17, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Financial Proceeds - The gross proceeds from the offering are expected to be approximately $10 million before deducting fees and expenses [3]. - If fully exercised, the Series Warrants could provide an additional gross proceeds of approximately $20 million [3]. - The net proceeds will be used for working capital and general corporate purposes [3]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications [6]. - The company focuses on optical genome mapping (OGM) solutions, diagnostic services, and software, with a mission to transform genome analysis [6]. - Bionano also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology [6].